PMC6159268_01
A 32-year-old pregnant female with Hodgkin's lymphoma. Pregnancy week 23 (a, e; arrowheads). Coronal T1 weighted (a-c), coronal maximum intensity projection diffusion-weighted (d) and coronal short tau inversion-recovery (e) whole-body MRI showing bilateral supraclavicular, cardiophrenic and mediastinal lymph node involvement (a-d; arrows).
bjrcr.20150293.g001.jpg
PMC6159268_01_bjrcr.20150293.g001.jpg
f1
Pregnancy week 30 (a, e; arrowheads). Coronal T1 weighted (a-c), coronal maximum intensity projection diffusion-weighted (d) and coronal short tau inversion-recovery (e) whole-body MRI showing progression of the disease with right axillary involvement (c; arrows) and further enlargement of other lymph nodes involved (a-d; arrows).
bjrcr.20150293.g002.jpg
PMC6159268_01_bjrcr.20150293.g002.jpg
f2
Images from scanning performed 2 weeks after delivery. Coronal T1 weighted (a-c), coronal maximum intensity projection diffusion-weighted (d) and coronal short tau inversion-recovery (e) whole-body MRI showing dimensional decrease of the axillary, cardiophrenic, right supraclavicular and mediastinal lymph nodes (a-d; arrows), a slight enlargement of the spleen and of left supraclavicular lymphadenopathy (b, d; arrowheads). Note also a still enlarged uterus after delivery (b; circle).
bjrcr.20150293.g003.jpg
PMC6159268_01_bjrcr.20150293.g003.jpg
f3
Ultrasound and WB-MRI were then performed to assess the response to treatment and showed progression of the supraclavicular lymphadenopathy and an enlargement of the longest axial diameter of the spleen from 11 to 14.5 cm, concluding that the disease was a resistant lymphoma (Figure 3).
Images from scanning performed 2 weeks after delivery. Fludeoxyglucose-positron emission tomography/CT images (a-e) showing multiple areas of increased uptake in cardiophrenic, bilateral supraclavicular and mediastinal lymph nodes (a-e; arrows).
bjrcr.20150293.g004.jpg
PMC6159268_01_bjrcr.20150293.g004.jpg
f4
Images from scanning performed 1 month after the end of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone regimen. Coronal maximum intensity projection diffusion-weighted (a), fludeoxyglucose- positron emission tomography/CT (b) and fludeoxyglucose-positron emission tomography (c) images showing complete remission of the disease.
bjrcr.20150293.g005.jpg
PMC6159268_01_bjrcr.20150293.g005.jpg
f5